Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Evaluation of BCL-6, CD10, CD138 and MUM-1 Expression in Diffuse Large B-Cell Lymphoma patients: CD138 is a Marker of Poor Prognosis

  • Bodoor, Khaldon (Department of Applied Biology, Faculty of Science and Arts, Jordan University of Science and Technology) ;
  • Matalka, Ismail (Department of Pathology, Jordan University of Science and Technology) ;
  • Hayajneh, Rami (Department of Applied Biology, Faculty of Science and Arts, Jordan University of Science and Technology) ;
  • Haddad, Yazan (Department of Applied Biology, Faculty of Science and Arts, Jordan University of Science and Technology) ;
  • Gharaibeh, Waleed (Department of Biology, University of Jordan)
  • Published : 2012.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

The diffuse large B-cell lymphoma (DLBCL) encompasses two major groups of tumors with uneven survival outcomes - germinal center B-cell (GCB) and non-germinal center B-cell (non-GCB). In the present study, we investigated the expression of GCB markers (BCL-6 and CD10) and non-GCB markers (CD138 and MUM-1) in an effort to evaluate their prognostic value. Paraffin-embedded tumor biopsies of 46 Jordanian DLBCL patients were analyzed, retrospectively, by immunohistochemistry to investigate the expression of BCL-6, CD10, CD138 and MUM-1. In addition, survival curves were calculated with reference to marker expression, age, sex and nodal involvement. Positive expression of BCL-6, CD10, CD138 and MUM-1 was shown in 78%, 61%, 39% and 91% of the cases, respectively, that of BCL-6 being associated with better overall survival (p = 0.02), whereas positive CD138 was linked with poor overall survival (p = 0.01). The expression of CD10 and MUM-1 had no impact on the overall survival. Among the clinical characteristics studied, diagnosis at an early age, nodal involvement and maleness were associated with a higher overall survival for DLBCL patients. Our results underline the importance of BCL-6 as a marker of better prognosis and CD138 as a marker of poor prognosis for DLBCL patients.

Keywords

References

  1. Alizadeh AA, Eisen MB, Davis RE, et al (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403, 503-11. https://doi.org/10.1038/35000501
  2. Barrans SL, O'Connor SJ, Evans PA, et al (2002). Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol, 117, 322-32. https://doi.org/10.1046/j.1365-2141.2002.03435.x
  3. Berglund M, Thunberg U, Amini RM, et al (2005). Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol, 18, 1113-20. https://doi.org/10.1038/modpathol.3800396
  4. Braaten KM, Betensky RA, De Leval L, et al (2003). BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res, 9, 1063-9.
  5. Breslow N A (1970). Generalized kruskal-wallis test for comparing K samples subject to unequal pattern of censorship. Biometrika, 57, 579-94. https://doi.org/10.1093/biomet/57.3.579
  6. Camilleri-Broet S, Criniere E, Broet P, et al (2006). A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood, 107, 190-6. https://doi.org/10.1182/blood-2005-03-1024
  7. Chang CC, McClintock S, Cleveland RP, et al (2004). Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol, 28, 464-70. https://doi.org/10.1097/00000478-200404000-00005
  8. Coiffier B, Lepage E, Briere J, et al (2002). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 346, 235-42. https://doi.org/10.1056/NEJMoa011795
  9. Colomo L, Lopez-Guillermo A, Perales M, et al (2003). Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood, 101, 78-84. https://doi.org/10.1182/blood-2002-04-1286
  10. De Paepe P, De Wolf-Peeters C (2007). Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. Leukemia, 21, 37-43. https://doi.org/10.1038/sj.leu.2404449
  11. Dogan A, Bagdi E, Munson P, et al (2000). CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol, 24, 846-52. https://doi.org/10.1097/00000478-200006000-00010
  12. Fabiani B, Delmer A, Lepage E, et al (2004). CD10 expression in diffuse large B-cell lymphomas does not influence survival. Virchows Arch, 445, 545-51. https://doi.org/10.1007/s00428-004-1129-7
  13. Groves FD, Linet MS, Travis LB, et al (2000). Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst, 92, 1240-51. https://doi.org/10.1093/jnci/92.15.1240
  14. Haarer CF, Roberts RA, Frutiger YM, et al (2006). Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival. Arch Pathol Lab Med, 130, 1819-24.
  15. Haddadin WJ (2005). Malignant lymphoma in Jordan: a retrospective analysis of 347 cases according to the World Health Organization classification. Ann Saudi Med, 25, 398-403.
  16. Hallermann C, Niermann C, Fischer RJ, et al (2007). New prognostic relevant factors in primary cutaneous diffuse large B-cell lymphomas. J Am Acad Dermatol, 56, 588-97. https://doi.org/10.1016/j.jaad.2006.12.026
  17. Hans CP, Weisenburger DD, Greiner TC, et al (2004). Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, 275-82. https://doi.org/10.1182/blood-2003-05-1545
  18. Harada S, Suzuki R, Uehira K, et al (1999). Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10+ groups may constitute clinically relevant subtypes. Leukemia, 13, 1441-7. https://doi.org/10.1038/sj.leu.2401487
  19. Harris NL, Jaffe ES, Stein H, et al (1994). A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 84, 1361-92.
  20. Hoffmann C, Tiemann M, Schrader C, et al (2005). AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping. Blood, 106, 1762-9. https://doi.org/10.1182/blood-2004-12-4631
  21. Hunt KE, Reichard KK (2008). Diffuse large B-cell lymphoma. Arch Pathol Lab Med, 132, 118-24.
  22. Jourdan M, Ferlin M, Legouffe E, et al (1998). The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol, 100, 637-46. https://doi.org/10.1046/j.1365-2141.1998.00623.x
  23. Kaplan EL, Meier P (1958). Nonparametric estimation from incomplete observations. J Amer Statist Assoc, 53, 457-81. https://doi.org/10.1080/01621459.1958.10501452
  24. Kojima Y, Tsurumi H, Goto N, et al (2006). Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome. Eur J Haematol, 76, 465-72. https://doi.org/10.1111/j.1600-0609.2006.00631.x
  25. Lin CH, Kuo KT, Chuang SS, et al (2006). Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. Clin Cancer Res, 12, 1152-6. https://doi.org/10.1158/1078-0432.CCR-05-1699
  26. Linderoth J, Jerkeman M, Cavallin-Stahl E, et al (2003). Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study. Clin Cancer Res, 9, 722-8.
  27. Liu YH, Xu FP, Zhuang HG, et al (2008). Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients. Hum Pathol, 39, 875-84. https://doi.org/10.1016/j.humpath.2007.10.013
  28. Lopez Guillermo A, Montserrat E (1992). Large-cell lymphomas: the International Prognostic Index. Sangre (Barc), 37, 329-30.
  29. Lossos IS, Jones CD, Warnke R, et al (2001). Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood, 98, 945-51. https://doi.org/10.1182/blood.V98.4.945
  30. Lossos IS, Levy R (2003). Diffuse large B-cell lymphoma: insights gained from gene expression profiling. Int J Hematol, 77, 321-9. https://doi.org/10.1007/BF02982638
  31. Lossos IS, Morgensztern D (2006). Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol, 24, 995-1007. https://doi.org/10.1200/JCO.2005.02.4786
  32. Magomedova AU, Vorob'ev AI (2008). International prognostic index in diffuse B large cell lymphosarcoma. Ter Arkh, 80, 71-6.
  33. Mann HB, Whitney DR (1947). On a test of whether one of two random variables is stochastically larger than the other. Annals of Mathematical Statistics, 18, 50-60. https://doi.org/10.1214/aoms/1177730491
  34. Mantel N (1966). Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep, 50, 163-70.
  35. Muris JJ, Meijer CJ, Vos W, et al (2006). Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol, 208, 714-23. https://doi.org/10.1002/path.1924
  36. Oh YH, Park CK (2006). Prognostic evaluation of nodal diffuse large B cell lymphoma by immunohistochemical profiles with emphasis on CD138 expression as a poor prognostic factor. J Korean Med Sci, 21, 397-405. https://doi.org/10.3346/jkms.2006.21.3.397
  37. Ohshima K, Kawasaki C, Muta H, et al (2001). CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. Histopathology, 39, 156-62. https://doi.org/10.1046/j.1365-2559.2001.01196.x
  38. Phan RT, Dalla-Favera R (2004). The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature, 432, 635-9. https://doi.org/10.1038/nature03147
  39. Pileri SA, Dirnhofer S, Went P, et al (2002). Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. Histopathology, 41, 482-509. https://doi.org/10.1046/j.1365-2559.2002.01538.x
  40. Pileri SA, Gaidano G, Zinzani PL, et al (2003). Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol, 162, 243-53. https://doi.org/10.1016/S0002-9440(10)63815-1
  41. Saez AI, Saez AJ, Artiga MJ, et al (2004). Building an outcome predictor model for diffuse large B-cell lymphoma. Am J Pathol, 164, 613-22. https://doi.org/10.1016/S0002-9440(10)63150-1
  42. Sjo LD, Poulsen CB, Hansen M, et al (2007). Profiling of diffuse large B-cell lymphoma by immunohistochemistry: identification of prognostic subgroups. Eur J Haematol, 79, 501-7. https://doi.org/10.1111/j.1600-0609.2007.00976.x
  43. Tsuboi K, Iida S, Inagaki H, et al (2000). MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia, 14, 449-56. https://doi.org/10.1038/sj.leu.2401696
  44. Tzankov A, Pehrs AC, Zimpfer A, et al (2003). Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases. J Clin Pathol, 56, 747-52. https://doi.org/10.1136/jcp.56.10.747
  45. Uherova P, Ross CW, Schnitzer B, et al (2001). The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma. Am J Clin Pathol, 115, 582-8. https://doi.org/10.1309/84GE-U85A-FMU0-7AUV
  46. Winter JN, Weller EA, Horning SJ, et al (2006). Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood, 107, 4207-13. https://doi.org/10.1182/blood-2005-10-4222
  47. Wright G, Tan B, Rosenwald A, et al (2003). A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A, 100, 9991-6. https://doi.org/10.1073/pnas.1732008100
  48. Xu Y, McKenna RW, Molberg KH, et al (2001). Clinicopathologic analysis of CD10+ and CD10- diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2. Am J Clin Pathol, 116, 183-90. https://doi.org/10.1309/J7RN-UXAY-55GX-BUNK
  49. Zinzani PL, Dirnhofer S, Sabattini E, et al (2005). Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. Haematologica, 90, 341-7.

Cited by

  1. Prognostic Values of Various Clinical Factors and Genetic Subtypes for Diffuse Large B-cell lymphoma Patients: A Retrospective Analysis of 227 Cases vol.14, pp.2, 2013, https://doi.org/10.7314/APJCP.2013.14.2.929
  2. Evaluation of BCL6 and MUM1 Expression in Patients with Diffuse Large B cell Lymphoma and their Correlations with Staging and Prognosis in Iran vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.83
  3. Production and characterization of monoclonal antibodies specific for canine CD138 (syndecan-1) for nuclear medicine preclinical trials on spontaneous tumours vol.15, pp.3, 2017, https://doi.org/10.1111/vco.12233
  4. Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs—syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin’s lymphoma vol.37, pp.9, 2016, https://doi.org/10.1007/s13277-016-5118-7
  5. Machine learning-based classification of diffuse large B-cell lymphoma patients by eight gene expression profiles vol.5, pp.5, 2016, https://doi.org/10.1002/cam4.650
  6. Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer vol.9, pp.1, 2016, https://doi.org/10.1186/s13048-016-0232-0
  7. Prognostic nutritional index as a predictor of prognosis in patients with diffuse large B cell lymphoma vol.129, pp.11-12, 2017, https://doi.org/10.1007/s00508-016-1077-7
  8. High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B-symptoms vol.184, pp.2, 2018, https://doi.org/10.1111/bjh.15703